We are live on ! Find out more
MRVI icon

Maravai LifeSciences

204 hedge funds and large institutions have $1.35B invested in Maravai LifeSciences in 2023 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 96 increasing their positions, 55 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

75% more call options, than puts

Call options by funds: $3.12M | Put options by funds: $1.78M

75% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 55

34% more capital inflows, than outflows

Capital inflows: $322M | Capital outflows: $241M

6.08% more ownership

Funds ownership: 96.15% → 102.22% (+6.1%)

7% less funds holding

Funds holding: 220 → 204 (-16)

38% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 45

Holders
204
Holders Change
-16
Holders Change %
-7.27%
% of All Funds
3.23%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
28
Increased
96
Reduced
55
Closed
45
Calls
$3.12​M
Puts
$1.78​M
Net Calls
+$1.33​M
Net Calls Change
+$10.9​M

MRVI Hedge Fund Activity: Q3 2023 in Review

204 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2023, worth a combined $1.35B — down 15% from $1.58B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of MRVI and 28 opened new positions — a net loss of 17 holders — while 55 trimmed existing stakes and 96 added.

The largest buyer was Millennium Management, adding an estimated $44.4M. The largest seller was Massachusetts Financial Services, cutting an estimated $33M.

  • 204 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2023, down from 220 in Q2 2023.
  • Funds reported $1.35B of Maravai LifeSciences stock for Q3 2023, down 15% quarter-over-quarter.
  • 28 funds opened new Maravai LifeSciences positions in Q3 2023 and 45 closed out, a net change of -17 holders.
  • The largest Maravai LifeSciences buyer in Q3 2023 was Millennium Management, an estimated $44.4M added.
  • The largest Maravai LifeSciences seller in Q3 2023 was Massachusetts Financial Services, an estimated $33M sold.

Based on aggregated 13F filings for Q3 2023.